Pharma Trends for 2026: Rare Diseases, Neuro, and Obesity with John Flavin

Key Pharma Themes for 2026

• 🎯 Neuro and rare diseases are highlighted as significant areas for focus in 2026, with a robust M&A environment in 2025 already showing strong activity in the neuro space.
• 💡 The FDA's favorable movements toward protocol adjustments are expected to accelerate development in rare diseases, with a recent non-profit approval paving the way for new drug approval pathways.
• 🚀 The obesity market is poised for an exciting year, with oral drug approvals from Novo and expected approvals from Lily, expanding patient access beyond injections.

Investment and Capital Flow

• 💰 Venture capital firms are recycling capital from M&A windfalls into earlier-stage innovation, evidenced by significant follow-on deals at the end of 2025.
• 📈 As the IPO market is expected to open in 2026, capital is anticipated to move upstream, seeking earlier opportunities in next-generation drugs.

Broader Innovation Areas

• 💖 The cardio metabolic space, including diabetes and heart health, is expected to see substantial activity in deal-making and innovation.
• 🧬 Emerging technologies like CRISPR, cell therapy, and gene therapy are making more cures available, moving from early scientific work to practical applications.
• 🔬 AI-enabled life sciences companies, particularly those focused on diagnostic tools for precision medicine, will continue to attract attention.
• 🏥 Oncology remains a critical area, with ongoing research into new modalities for treating a range of cancers, especially incurable diseases.